Farrokh Modabber

Responsible for Research Strengthening Component of TDR/WHO in Geneva among others, prior to retirement with emphasis on Good Clinical Practices in clinical studies. Then as the Director of IDRI (Seattle) involved in the early stages of the clinical development of the first defined vaccine against leishmaniases. At DNDi (Geneva) managed the clinical development of combination therapy for visceral leishmaniasis. Now a consultant in DNDi for the development of an immune response modifier (CpG).